JP2009500431A5 - - Google Patents

Download PDF

Info

Publication number
JP2009500431A5
JP2009500431A5 JP2008520685A JP2008520685A JP2009500431A5 JP 2009500431 A5 JP2009500431 A5 JP 2009500431A5 JP 2008520685 A JP2008520685 A JP 2008520685A JP 2008520685 A JP2008520685 A JP 2008520685A JP 2009500431 A5 JP2009500431 A5 JP 2009500431A5
Authority
JP
Japan
Prior art keywords
complex
pharmaceutically acceptable
composition according
angiopep
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008520685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009500431A (ja
JP5436856B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2006/001165 external-priority patent/WO2007009229A1/en
Publication of JP2009500431A publication Critical patent/JP2009500431A/ja
Publication of JP2009500431A5 publication Critical patent/JP2009500431A5/ja
Application granted granted Critical
Publication of JP5436856B2 publication Critical patent/JP5436856B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008520685A 2005-07-15 2006-07-14 薬学的複合体における担体としてのアプロチニンポリペプチドの使用 Expired - Fee Related JP5436856B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69937505P 2005-07-15 2005-07-15
US60/699,375 2005-07-15
US75853206P 2006-01-13 2006-01-13
US60/758,532 2006-01-13
PCT/CA2006/001165 WO2007009229A1 (en) 2005-07-15 2006-07-14 Use of aprotinin polypeptides as carriers in pharmaceutical conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012230853A Division JP2013047249A (ja) 2005-07-15 2012-10-18 薬学的複合体における担体としてのアプロチニンポリペプチドの使用

Publications (3)

Publication Number Publication Date
JP2009500431A JP2009500431A (ja) 2009-01-08
JP2009500431A5 true JP2009500431A5 (enExample) 2009-09-03
JP5436856B2 JP5436856B2 (ja) 2014-03-05

Family

ID=37668389

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008520685A Expired - Fee Related JP5436856B2 (ja) 2005-07-15 2006-07-14 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
JP2012230853A Withdrawn JP2013047249A (ja) 2005-07-15 2012-10-18 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
JP2015112969A Pending JP2015163641A (ja) 2005-07-15 2015-06-03 薬学的複合体における担体としてのアプロチニンポリペプチドの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012230853A Withdrawn JP2013047249A (ja) 2005-07-15 2012-10-18 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
JP2015112969A Pending JP2015163641A (ja) 2005-07-15 2015-06-03 薬学的複合体における担体としてのアプロチニンポリペプチドの使用

Country Status (15)

Country Link
US (3) US8969310B2 (enExample)
EP (4) EP2233156B1 (enExample)
JP (3) JP5436856B2 (enExample)
CN (1) CN101262890B (enExample)
AU (1) AU2006272405B2 (enExample)
BR (1) BRPI0613005A8 (enExample)
CA (1) CA2614687C (enExample)
DK (2) DK2433653T3 (enExample)
ES (2) ES2744225T3 (enExample)
HR (1) HRP20130720T1 (enExample)
PL (1) PL2233156T3 (enExample)
PT (1) PT2233156E (enExample)
RU (2) RU2422143C2 (enExample)
SI (1) SI2233156T1 (enExample)
WO (1) WO2007009229A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1747747B (zh) 2003-01-06 2012-09-05 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
CN101160403B (zh) 2005-02-18 2014-08-13 安吉奥开米公司 转运化合物穿过血脑屏障的分子
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
JP5436856B2 (ja) 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2789628A3 (en) 2007-05-29 2015-03-04 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
ES2488668T3 (es) * 2007-05-29 2014-08-28 Angiochem Inc. Polipéptidos de tipo aprotinina para administrar agentes conjugados con los mismos a tejidos
MX2010006925A (es) * 2007-12-20 2011-05-02 Angiochem Inc Conjugados de polipeptido-acido nucleico y sus usos.
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
RU2518240C2 (ru) 2008-04-18 2014-06-10 Ангиочем Инк. Композиция, на основе гидрофобных агентов и способ ее получения(варианты)
RU2531591C2 (ru) * 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
MX2011005963A (es) * 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
DE102009006228A1 (de) 2009-01-27 2010-07-29 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Liposomale Zusammensetzung zur Behandlung von Hirnmetastasen
JP2010229122A (ja) * 2009-03-06 2010-10-14 Kumamoto Univ 抗癌剤、医薬、及び癌疾患の検査薬
AU2010239069B2 (en) * 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
EP2437790B1 (en) 2009-06-03 2019-02-20 Immunogen, Inc. Conjugation methods
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
WO2012037687A1 (en) * 2010-09-23 2012-03-29 Angiochem Inc. Therapeutic polypeptides and uses thereof
CN102085157B (zh) * 2011-01-27 2012-02-01 中国水产科学研究院黄海水产研究所 扇贝抗氧化肽纳米脂质体及其制备方法
CN102614524A (zh) * 2011-02-01 2012-08-01 复旦大学 低密度脂蛋白受体相关蛋白配体多肽修饰的脑肿瘤靶向基因递释复合物
TR201902180T4 (tr) 2011-03-29 2019-03-21 Immunogen Inc Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
WO2014026283A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
RU2661083C2 (ru) * 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
RU2015121818A (ru) * 2012-11-12 2017-01-10 Ангиохем Инк. Конъюгаты антител с полипептидами-производными апротинина
EP3018143B1 (en) 2013-07-03 2019-05-29 Seoul National University R&DB Foundation Chicken antibody transformed into cysteine and site-specific conjugation using same
AU2014284496A1 (en) 2013-07-03 2016-01-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for treating cognitive dysfunction
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
EP3171886A4 (en) 2014-07-21 2018-01-24 The Arizona Board of Regents On Behalf of the University of Arizona Ang-(1-7) derviative oligopeptides and methods for using and producing the same
GB201502447D0 (en) 2015-02-13 2015-04-01 Univ Liverpool Method and apparatus for sample analysis
US10980892B2 (en) 2015-06-15 2021-04-20 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
US12419832B2 (en) 2018-01-29 2025-09-23 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
CN111529716B (zh) * 2020-06-02 2021-05-28 南方医科大学 一种多肽-紫杉醇偶联物及其应用

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US508697A (en) * 1893-11-14 Jar or bottle receiver
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
ES8407536A1 (es) * 1983-10-07 1984-10-01 Jumberca Sa Mejoras en los alimentadores de hilo para telares circulares de genero de punto dotados de dispositivos listadores.
ZA871844B (en) 1986-03-13 1988-05-25 Biotechnology Pty Ltd Method of assay of inhibin
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
JPH08504568A (ja) 1992-09-25 1996-05-21 コルバス・インターナショナル、インコーポレイテッド ウシ膵トリプシン阻害因子から誘導される因子VIIa−組織因子複合体の阻害因子
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
MX9307777A (es) 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
WO1994019692A1 (en) 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
WO1996031531A2 (en) 1995-04-04 1996-10-10 Advanced Bioconcept, Inc. Fluorescent peptides
JPH11504938A (ja) 1995-05-08 1999-05-11 サイオス インク. クニッツ型プロテアーゼ阻害因子
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
AU5908296A (en) 1995-05-31 1996-12-24 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector m olecules
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
WO1997033996A2 (en) 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
WO1997040160A1 (en) 1996-04-24 1997-10-30 Rijksuniversiteit Te Groningen A prokaryotic protein having functional and structural homology with the human p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein
WO1997040854A2 (en) 1996-05-01 1997-11-06 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU4907897A (en) 1996-10-11 1998-05-11 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP4116683B2 (ja) 1997-02-28 2008-07-09 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 徐放性局所送達製剤
DE69838544T2 (de) * 1997-03-04 2008-07-24 Savient Pharmaceuticals, Inc. Isolierung von gewebespezifischen peptidliganden und ihre verwendung zur ausrichtung von pharmazeutika auf zielorgane
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
CA2291074C (en) 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
AU768027B2 (en) 1999-02-24 2003-11-27 Uab Research Foundation, The Taxane derivatives for targeted therapy of cancer
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) * 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
CA2307393A1 (en) * 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
CA2355334A1 (en) 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
EP1337273A2 (en) 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1383492A4 (en) 2001-03-23 2008-12-24 Napro Biotherapeutics Inc MOLECULAR CONJUGATES FOR USE IN CANCER THERAPY
IL158418A0 (en) 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
EP1465618A2 (en) * 2001-12-20 2004-10-13 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
RU2196604C1 (ru) * 2001-12-21 2003-01-20 Северин Евгений Сергеевич Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
WO2003066859A2 (en) * 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
WO2004003145A2 (en) 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
CN1747747B (zh) * 2003-01-06 2012-09-05 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
WO2004093897A1 (en) * 2003-04-08 2004-11-04 Biotempt, B.V. Compositions for mucosal and oral administration comprising hcg fragments
US7374762B2 (en) 2003-05-14 2008-05-20 Immunogen, Inc. Drug conjugate composition
WO2004108071A2 (en) 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
AU2004253471B2 (en) * 2003-06-20 2010-05-13 Raptor Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CN100457775C (zh) 2003-08-08 2009-02-04 普洛图斯科学株式会社 具有脑定位活性的多肽及其用途
WO2005021579A2 (en) * 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
US20050058702A1 (en) 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
KR20090006221A (ko) 2004-07-26 2009-01-14 아스테리온 리미티드 연결체들
EP1799826B1 (en) 2004-09-29 2009-08-12 Children's Memorial Hospital siRNA-MEDIATED GENE SILENCING OF ALPHA SYNUCLEIN
WO2006089290A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
CN101160403B (zh) 2005-02-18 2014-08-13 安吉奥开米公司 转运化合物穿过血脑屏障的分子
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
AU2006247471A1 (en) 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
WO2006138343A2 (en) 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
JP5436856B2 (ja) 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
MX2008000994A (es) 2005-07-19 2008-03-19 Univ Illinois Agentes de transporte para cruzar la barrera hematoencefalica y hacia el interior de las celulas de cancer cerebral, y metodos para el uso de los mismos.
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
EP1934359A2 (en) 2005-09-08 2008-06-25 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
EP1951737A4 (en) 2005-11-01 2009-07-01 Alnylam Pharmaceuticals Inc INHIBITION OF INFLUENZA VIRUS REPLICATION BY RNA INTERFERENCE
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
KR101193722B1 (ko) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 엑센딘 융합 단백질
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(rap)-접합체 투여에 의한 간 질환의 치료
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
EP2789628A3 (en) 2007-05-29 2015-03-04 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8802631B2 (en) 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
WO2009070597A2 (en) 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns
MX2010006925A (es) 2007-12-20 2011-05-02 Angiochem Inc Conjugados de polipeptido-acido nucleico y sus usos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US11260133B2 (en) 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
RU2518240C2 (ru) 2008-04-18 2014-06-10 Ангиочем Инк. Композиция, на основе гидрофобных агентов и способ ее получения(варианты)
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
CA2745527A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
AU2010239069B2 (en) 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
US20100284921A1 (en) 2009-05-08 2010-11-11 Temple University - Of The Commonwealth System Of Higher Education Targeted nanoparticles for intracellular cancer therapy
AU2010258052A1 (en) 2009-06-11 2012-01-12 Angiochem Inc. Fusion proteins for delivery of GDNF and BDNF to the central nervous system
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
BR112012000908A2 (pt) 2009-07-14 2019-09-24 Mayo Found Medical Education & Res liberação de agentes ativos através da barreira hematoencefálica mediada por peptídeo em associação não covalente
MX2012004247A (es) 2009-10-06 2012-06-25 Angiochem Inc Composiciones y metodos para el transporte de agentes terapeuticos.
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
WO2011153642A1 (en) 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
WO2012037687A1 (en) 2010-09-23 2012-03-29 Angiochem Inc. Therapeutic polypeptides and uses thereof
WO2012068531A2 (en) 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2013056096A1 (en) 2011-10-13 2013-04-18 Angiochem Inc. Polypeptide-opioid conjugates and uses thereof
CN104136606A (zh) 2011-12-01 2014-11-05 安吉奥开米公司 靶向的艾杜糖-2-硫酸酯酶化合物
WO2013078564A2 (en) 2011-12-01 2013-06-06 Angiochem Inc. Targeted lysosomal enzyme compounds
WO2013185235A1 (en) 2012-06-15 2013-12-19 Angiochem Inc. Targeted iduronidase compounds
WO2014026283A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
EP2885321A4 (en) 2012-08-14 2016-03-30 Angiochem Inc CONJUGATES WITH AN ANTIBODY PART, A POLYPEPTIDE THROUGH THE BLOOD BRAIN BARRIER, AND A CYTOTOXIN
RU2015121818A (ru) 2012-11-12 2017-01-10 Ангиохем Инк. Конъюгаты антител с полипептидами-производными апротинина
GB201220474D0 (en) 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
US20150290341A1 (en) 2012-11-30 2015-10-15 Anglachem Inc. Targeted iduronate-2-sulfatase compounds
HK1179821A2 (en) 2013-05-28 2013-10-04 捷迅视讯器材有限公司 High voltage discharge protection device and radio frequency transmission apparatus using the same
WO2014194429A1 (en) 2013-06-06 2014-12-11 Angiochem Inc. Targeted enzyme compounds and uses thereof
WO2014194428A1 (en) 2013-06-06 2014-12-11 Angiochem Inc. Targeted heparan sulfatase compounds

Similar Documents

Publication Publication Date Title
RU2008105677A (ru) Усиление действия противораковых агентов
Yan et al. Chiral protein supraparticles for tumor suppression and synergistic immunotherapy: an enabling strategy for bioactive supramolecular chirality construction
JP2025066807A (ja) 生体直交型組成物
CN103402545B (zh) 疏水性经修饰肽及其在肝特异性靶向中的用途
CN111093708B (zh) 生物正交组合物
Garsky et al. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy
JP6207509B2 (ja) 固形腫瘍を治療するためのfap活性化プロテアソーム阻害剤
JP2010514839A5 (enExample)
RU2010137915A (ru) Полипептиды апортинина для транспорта соединения через гематоэнцефалический барьер
Mai et al. Targeting legumain as a novel therapeutic strategy in cancers
CN102026667B (zh) 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
JP2021506910A (ja) EphA2に特異的な二環ペプチドリガンド
ES2602731T3 (es) Nueva composición y métodos para el tratamiento de enfermedades relacionadas con el sistema inmunitario
Yang et al. Disulfide bond reduction-triggered molecular hydrogels of folic acid–Taxol conjugates
JP2017521371A5 (enExample)
Egorova et al. Delivery of theranostic nanoparticles to various cancers by means of integrin-binding peptides
US20110123988A1 (en) Antisense compounds and methods for diagnostic imaging
CN101815724A (zh) 用于将轭合至其的试剂递送至组织的抑肽酶样多肽
CN103687624A (zh) 靶向的聚合缀合物和其用途
Jadhav et al. Peptide–drug conjugates as next-generation therapeutics: exploring the potential and clinical progress
McGonigle et al. Neuropilin-1 drives tumor-specific uptake of chlorotoxin
JP6032854B2 (ja) 抗新生物及び抗血管新生活性を有する環状ペプチド
Hu et al. Targeted modification of the cationic anticancer peptide HPRP-A1 with iRGD to improve specificity, penetration, and tumor-tissue accumulation
Chen et al. Retro-inverso carbohydrate mimetic peptides with annexin1-binding selectivity, are stable in vivo, and target tumor vasculature
JP2010524968A5 (enExample)